{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:44:00Z","timestamp":1778636640247,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>The COVID-19 is affecting thousands of peoples day by day and continues to spread across the world. The present review has focused on promising repurposing drugs, including remdesivir, lopinvar\/retinovar, favipiravir, hydroxychloroquine, monoclonal antibodies and vaccines against the SARS-CoV-2 infection. Besides, our review has also focused on many organizations that are in the race to develop vaccines using various approaches including DNA, RNA, viral vectors and subunit proteins against this highly contagious respiratory disease. The spike protein is being studied by scientists all over the world to develop potential vaccines. The antiviral drugs, antibodies and vaccines developed by various researchers around the world have entered clinical trials in humans. The current clinical trials for antiviral agents and vaccines with promising outcomes are being discussed. So far, four vaccines developed by the Pfizer-BioNTech vaccine, the Johnson and Johnson vaccine and two AstraZeneca vaccines (produced by SKBio in the Republic of Korea and Serum Institute of India) are approved by the World Health Organization for public use.<\/jats:p>","DOI":"10.3389\/fmolb.2021.637378","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T04:21:07Z","timestamp":1623212467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials"],"prefix":"10.3389","volume":"8","author":[{"given":"Jeyanthi","family":"Venkadapathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkat Kumar","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saravanan","family":"Sekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhi","family":"Venkatapathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41541-021-00323-6","article-title":"Access to and Equitable Distribution of COVID-19 Vaccine in Low-Income Countries","volume":"6","author":"Acharya","year":"2021","journal-title":"NPJ Vaccin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"635337","DOI":"10.3389\/fmolb.2021.635337","article-title":"Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19","volume":"8","author":"Bezbaruah","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"635245","DOI":"10.3389\/fmolb.2021.635245","article-title":"Perspectives on RNA Vaccine Candidates for COVID-19","volume":"8","author":"Borah","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B7","article-title":"Information about Johnson & Johnson\u2019s Janssen COVID-19 Vaccine","volume-title":"National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases","year":""},{"key":"B8","article-title":"Information about the Pfizer-BioNTech COVID-19 Vaccine","volume-title":"National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases","year":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3785\/j.issn.1008-9292.2020.03.03","article-title":"A Pilot Study of Hydroxychloroquine Sulfate in Patients with Common 2019 Coronavirus Disease-19","volume":"49","author":"Chen","year":"2020","journal-title":"J. Zhejiang Univ. (Med Sci."},{"key":"B10","volume-title":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). ArcGIS","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (Favipiravir) and Related Compounds: Novel Broad-Spectrum Inhibitors of RNA Viral Infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-randomized Clinical Trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir Is a Direct-Acting Antiviral that Inhibits RNA-dependent RNA Polymerase from Severe Acute Respiratory Syndrome Coronavirus 2 with High Potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.17485\/IJST\/v13i36.1116","article-title":"COVID-19 Outbreak: An Overview and India's Perspectives on the Management of Infection","volume":"13","author":"Jeyanthi","year":"2020","journal-title":"Indian J. Sci. Technol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 Vaccine Candidate Appears Safe and Effective","volume":"397","author":"Jones","year":"2021","journal-title":"The Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41541-020-0188-3","article-title":"COVID-19 Vaccines: Breaking Record Times to First-In-Human Trials","volume":"5","author":"Kim","year":"2020","journal-title":"NPJ Vaccin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"107672","DOI":"10.1016\/j.pharmthera.2020.107672","article-title":"Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19","volume":"216","author":"Lei","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in Patients Admitted to Hospital with Severe or Critical COVID-19: a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab Treatment in COVID\u201019: A Single center Experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection","volume":"50","author":"Molina","year":"2020","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"key":"B23","volume-title":"Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","year":"2021"},{"key":"B24","volume-title":"An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers","year":""},{"key":"B25","volume-title":"Lopinavir\/Ritonavir for the Treatment of COVID-19 Positive Patients with Cancer and Immune Suppression in the Last Year","year":""},{"key":"B26","volume-title":"Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients with COVID-19","year":""},{"key":"B27","volume-title":"Phase III Double-Blind, Placebo-Controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","year":""},{"key":"B28","article-title":"Which Covid-19 Drugs Work Best. MIT Technology Review","author":"Regalado","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1111\/bph.15072","article-title":"Current Pharmacological Treatments for COVID\u201019: What's Next?","volume":"177","author":"Scavone","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 Infection: Emergence, Transmission, and Characteristics of Human Coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J. Adv. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100682","DOI":"10.1016\/j.nmni.2020.100682","article-title":"A Short Review on Antibody Therapy for COVID-19","volume":"35","author":"Venkat Kumar","year":"2020","journal-title":"New Microbes and New Infections"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in Adults with Severe COVID-19: a Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial","volume":"395","author":"Wang","year":"2020","journal-title":"The Lancet"},{"key":"B34","unstructured":"Draft Landscape of COVID-19 Candidate Vaccines2020"},{"key":"B35","unstructured":"The Sinopharm COVID-19 Vaccine: What You Need to Know 20212021"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.15.043166","article-title":"Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2","author":"Williamson","year":"2020","journal-title":"bioRxiv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s13337-020-00650-7","article-title":"Vaccines and Drugs under Clinical Trials for Prevention and Treatment of COVID-19","volume":"32","author":"Yadav","year":"2021","journal-title":"VirusDis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"105982","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine Storm and Immunomodulatory Therapy in COVID-19: Role of Chloroquine and anti-IL-6 Monoclonal Antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.637378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T04:21:20Z","timestamp":1623212480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.637378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":37,"alternative-id":["10.3389\/fmolb.2021.637378"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.637378","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"article-number":"637378"}}